Transcode Therapeutics (RNAZ) Other Working Capital Changes (2020 - 2026)

Transcode Therapeutics (RNAZ) has reported Other Working Capital Changes for 7 consecutive years, with $644024.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Working Capital Changes rose 239.39% year-over-year to $644024.0; the trailing twelve-month figure through Jun 2026 stood at $1.5 million (up 518.04% YoY), and the FY2025 full-year result was -$477261.0, down 15.76% from the prior year.
• Other Working Capital Changes slipped to $644024.0 in Q2 2026 per RNAZ's latest filing, from $695656.0 in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $1.8 million in Q3 2022 and bottomed at -$1.4 million in Q2 2023.
• Historically, Other Working Capital Changes has averaged $9455.4 across 5 years, with a median of -$119218.5 in 2022.
• The sharpest annual moves came in 2022 and 2023: Other Working Capital Changes tumbled 7254.49% in 2022, then soared 641.83% in 2023.
• Over 5 years, Other Working Capital Changes stood at -$240708.0 in 2022, then jumped by 40.13% to -$144123.0 in 2023, then climbed by 20.77% to -$114189.0 in 2024, then sank by 698.52% to -$911823.0 in 2025, then soared by 170.63% to $644024.0 in 2026.
• According to Business Quant data, Other Working Capital Changes over the past three periods registered $644024.0, $695656.0, and -$911823.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.